Does semaglutide reduce alcohol intake in Danish patients with alcohol use disorder and comorbid obesity? Trial protocol of a randomised, double-blinded, placebo-controlled clinical trial (the SEMALCO trial)
Klausen M, Kuzey T, Pedersen J, Justesen S, Rasmussen L, Knorr U, Mason G, Ekstrøm C, Holst J, Koob G, Benveniste H, Volkow N, Knudsen G, Vilsbøll T, Fink-Jensen A. Does semaglutide reduce alcohol intake in Danish patients with alcohol use disorder and comorbid obesity? Trial protocol of a randomised, double-blinded, placebo-controlled clinical trial (the SEMALCO trial). BMJ Open 2025, 15: e086454. PMID: 39779270, PMCID: PMC11749217, DOI: 10.1136/bmjopen-2024-086454.Peer-Reviewed Original ResearchConceptsAlcohol use disorderUse disorderGamma-aminobutyric acidComorbid obesityAlcohol cue reactivityCognitive behavioral therapyHeavy drinking daysWhite matter tract integrityBrain gamma-aminobutyric acidGlucagon-like peptide-1Alcohol consumptionMental health disordersReduce alcohol consumptionClinical trialsCue reactivityPlacebo-controlled clinical trialBehavioral therapyDrinking daysFunctional connectivityGLP-1 receptor agonist semaglutideWeeks of treatmentDouble-blind clinical trialTract integrityEthics Committee of the Capital Region of DenmarkHealth disorders
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply